From historical perspectives to modern therapy: A review of current and future biological treatments for Crohn’s disease

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 3, 2015, Pages 143-159

  Vizuete, John A ^a   Randall, Charles W ^b   Taboada, Carlo M ^b   Martinez, Nicholas ^a   Alvarez, John J ^a   Garapati, Karthik V ^a   Malakouti, Mazyar ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Gastroenterology Consultants of San Antonio   (United States)

Author keywords

anti TNF; biologics; Crohns Disease; Inflammatory Bowel Disease

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; USTEKINUMAB; VEDOLIZUMAB; VERCIRNON;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISEASE SEVERITY; HISTORY OF MEDICINE; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; ULCERATIVE COLITIS;

EID: 84927799117     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15576462     Document Type: Review

References (113)

1. Ananthakrishnan A. Hur C. Korzenik R. (2012) Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci 57: 472–480.
2. Andoh A. Yagi Y. Shioya M. Nishida A. Tsujikawa T. Fujiyama Y. (2008) Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 14: 5154.
3. Ardizzone S. Puttini P. Cassinotti A. Porro G. (2008) Extraintestinal manifestations of inflammatory bowel disease. Digest Liver Dis 40: 253–259.
4. Aufses A. Jr. (2001) The history of Crohn's disease. Surg Clin N Am 81: 1–11.
5. Bandzar S. Gupta S. Platt M. (2013) Crohn's disease: a review of treatment options and current research. Cell Immunol 286: 45–52.
6. Baumgart D. Sandborn W. (2012) Crohn's disease. Lancet 380: 1590–1605.
7. Bekker P. Schreiber S. Keshav S. (2007) PROTECT-1, prospective randomized oral therapy evaluation of CCX282-B (TRAFICET-EN) in Crohn's disease. Gut 56: A23.
8. Ben-Horin S. Yavzori M. Kopylov U. Picard O. Fudim E. Eliakim R. et al. (2011) Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohn's Colitis 5: 555–558.
9. Beutler B. Milsark I. Cerami A. (1985) Passive immunization against cachectin / tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–871.
10. Billioud V. Sandborn W. Peyrin-Biroulet L. (2011) Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 106: 674–684.
11. Bloomgren G. Richman S. Hotermans C. Subramanyam M. Goelz S. Natarajan A. et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Eng J Med 366: 1870–1880.
12. Bouhnik Y. Scemama G. Taï R. Matuchansky C. Rambaud J. Lémann M. et al. (1996) Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347: 215–219.
13. Bultman E. de Haar C. van Liere-Baron A. Verhoog H. West R. Kuipers E. et al. (2012) Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Alim Pharm Ther 35: 335–341.
14. Burakoff R. Barish C. Riff D. Pruitt R. Chey W. Farraye F. et al. (2006) A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 12: 558–565.
15. Burisch J. Jess T. Martinato M. Lakatos P. (2013) The burden of inflammatory bowel disease in Europe. J Crohns Colitis 7: 322–337.
16. Burmester G. Panaccione R. Gordon K. McIlraith M. Lacerda A. (2013) Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 72: 517–524.
17. Cheent K. Nolan J. Shariq S. Kiho L. Pal A. Arnold J. (2010). Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 4: 603–605.
18. Cheifetz A. Mayer L. (2005) Monoclonal antibodies, immunogenicity and associated infusion reactions. Mt Sin J Med 72: 250-256.
19. Cheifetz A. Smedley M. Martin S. Reiter M. Leone G. Mayer L. et al. (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98: 1315–1324.
20. Colombel J. Sandborn W. Allez M. Dupas J. Dewit O. D'Haens G. et al. (2014) Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 12: 423–431.
21. Colombel J. Sandborn W. Reinisch W. Mantzaris G. Kornbluth A. Rachmilewitz D. et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Eng J Med 362: 1383–1395.
22. Colombel J. Sandborn W. Rutgeerts P. Enns R. Hanauer S. Panaccione R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132: 52–65.
23. Cosnes J. Gower-Rousseau C. Seksik P. Cortot A. (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140:, 1785–1794.
24. Crohn B. Ginzburg L. Oppenheimer G. (1932) Regional ileitis: a pathologic and clinical entity. JAMA 99: 1323–1329.
25. D'Haens G. van Deventer S. van Hogezand R. Chalmers D. Kothe C. Baert F. et al. (1999) Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116: 1029–1034.
26. Da W. Zhu J. Wang L. Lu Y. (2013) Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis. Adv Ther 30: 541–553.
27. Das K. (1999) Relationship of extraintestinal involvements in inflammatory bowel disease (new insights into autoimmune pathogenesis). Dig Dis Sci 44: 1–13.
28. Elliott M. Maini R. Feldmann M. Long-Fox A. Charles P. Katsikis P. et al. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36: 1681–1690.
29. Feagan B. Greenberg G. Wild G. Fedorak R. Paré P. McDonald J. et al. (2008) Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol 6: 1370–1377.
30. Feagan B. Sandborn W. Baker J. Cominelli F. Sutherland L. Elson C. et al. (2005) A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease. Alim Pharm Ther 21: 373–384.
31. Feldman M. Maini R. (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 19: 163–169.
32. Ford A. Sandborn W. Khan K. Hanauer S. Talley N. Moayyedi P. (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106: 644–659.
33. Foster A. Jacobson K. (2013) Changing Incidence of inflammatory bowel disease: environmental influences and lessons learnt from the South Asia population. Front Pediatr 1: 1–7.
34. Friedman S. Blumberg R.S. (2012) Inflammatory bowel disease. In: Ed. Longo D.L. Fauci A.S. Kasper D.L. Hauser S.L. Jameson J. Loscalzo J. (eds), Harrison's Principles of Internal Medicine, 18th edn. New York, NY: Mc-Graw Hill, pp. 2477–2495.
35. Gawron L. Hammond C. Ernst L. (2013) perinatal pathologic examination of non-intact, second trimester fetal demise specimens: the value of standardization. Arch Pathol Lab Med 167: 326–331.
36. Ghosh S. Goldin E. Gordon F. Malchow H. Rask-Madsen J. Rutgeerts P. et al. (2003) Natalizumab for active Crohn's disease. N Eng J Med 348: 24–32.
37. Gordon F. Lai C. Hamilton M. Allison M. Srivastava E. Fouweather M. et al. (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121: 268–274.
38. Greenstein A. Sachar D. Mann D. Lachman P. Heimann T. Aufses A. Jr (1987) Spontaneous free perforation and perforated abscess in 30 patients with Crohn's disease. Ann Surg 205: 72–76.
39. Hanauer S. Feagan B. Lichtenstein G. Mayer L. Schreiber S. Colombel J. et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549.
40. Hanauer S. Sandborn W. Rutgeerts P. Fedorak R. Lukas M. MacIntosh D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC trial. Gastroenterology 130: 323–33.
41. Harris F. Bell G. Brunn H. (1933) Chronic cicatrizing enteritis: regional ileitis (Crohn). A new surgical entity. Surg Gynecol Obstet 57: 637–645.
42. Hart A. Ng S. (2011) Crohn's disease. M edicine 39: 229–236.
43. Hugot J. Chamaillard M. Zouali H. Lesage S. Cézard J. Belaiche J. et al. (2001) Association of NOD 2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599–603.
44. Ito H. Takazoe M. Fukuda Y. Hibi T. Kusugami K. Andoh A. et al. (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989–996.
45. Juillerat P. Wasan S. Fowler S. Friedman S. Pabby V. Coukas J. et al. (2013) Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis 19: 2457–2463.
46. Kane S. Horst S. Sandborn W. Becker B. Neis B. Moscandrew M. et al. (2012) Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 18: 2203–2208.
47. Keffer J. Probert L. Cazlaris H. Georgopoulos S. Kaslaris E. Kioussis D. et al. (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10: 4025–4031.
48. Keshav S. Johnson D. Bekker P. Schall T. (2009) PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate to severe Crohn's disease. Gastroenterology 136: A65.
49. Keshav S. Vaňásek T. Niv Y. Petryka R. Howaldt S. Bafutto M. et al. (2013) A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS On, 8: e60094.
50. Kirsner J. (1988) Historical aspects of inflammatory bowel disease. J Clin Gastroenterol 10: 286–297.
51. Kleinschmidt-deMasters B. Tyler K. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369–374.
52. Lichtenstein G. Hanauer S. Sandborn W. (2009) Practice Parameters Committee of American College of Gastroenterology; management of Crohn's disease in adults. Am J Gastroenterol 104: 465–483.
53. Lichtenstein G. Olson A. Travers S. Diamond R. Chen D. Pritchard M. et al. (2006) Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 101: 1030–1038.
54. Lichtenstein G. Panaccione R. Mallarkey G. (2008) Efficacy and safety of adalimumab in crohn's disease. Ther Adv Gastroenterol 1: 43–50.
55. Lichtenstein G. Rutgeerts P. Sandborn W. Sands B. Diamond R. Blank M. et al. (2012) A pooled analysis of infections, malignancy and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 107: 1051–1063.
56. Lichtenstein G. Thomsen O. Schreiber S. Lawrance I. Hanauer S. Bloomfield R. et al. (2010) Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 8: 600–609.
57. Lichtenstein G. Yan S. Bala M. Blank M. Sands B. (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease. Gastroenterology 128: 862–869.
58. Lockhart-Mummery H. Morson B. (1960) Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut 1: 87–105.
59. Loftus E. Schoenfeld P. Sandborn W. (2002) The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Alim Pharm Ther 16: 51–60.
60. MacDonald J. McDonald J. (2007) Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 24 January 2007. DOI: 10.1002/14651858.CD006097.pub2.
61. MacDonald T. Hatchings P. Choy M. Munch S. Cooke A. (1990) Tumor necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81: 301–305.
62. Mahadevan U. Cucchiara S. Hyams J. Steinwurz F. Nuti F. Travis S. et al. (2011) The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 106: 214–223.
63. Mahadevan U. Wolf D. Dubinsky M. Cortot A. Lee S. Siegel C. et al. (2013) Placental transfer of anti–tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11: 286–292.
64. Mannon P. Fuss I. Mayer L. Elson C. Sandborn W. Present D. et al. (2004) Anti–interleukin-12 antibody for active Crohn's disease. N Eng J Med 351: 2069–2079.
65. Ng S. Tang W. Ching J. Wong M. Chow C. Hui A. et al. (2013) Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology 145: 158–165.
66. Ogura Y. Bonen D. Inohara N. Nicolae D. Chen F. Ramos R. et al. (2001) A frameshift mutation in NOD 2 associated with susceptibility to Crohn's disease. Nature 411: 603–606.
67. Parsi M. Achkar J. Richardson S. Katz J. Hammel J. Lashner B. et al. (2002) Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123: 707–713.
68. Perez-Alvarez R. Pérez-de-Lis M. Ramos-Casals M. and BIOGEAS Study Group (2013) Biologics-induced autoimmune diseases. Curr Opin Rheumatol 25: 56–64.
69. Podolsky D. (2002) Inflammatory bowel disease. N Engl J Med. 347: 417–429.
70. Randall C. Vizuete J. Wendorf G. Ayyar B. Constantine G. (2012) Current and emerging strategies in the management of Crohn's disease. Best Pract Res Clin Gastroenterol 26: 601–610.
71. Rankin G. Watts H. Melnyk C. Kelley. M. Jr. (1979) National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77: 914–920.
72. Rosman Z. Shoenfeld Y. Zandman-Goddard G. (2013) Biologic therapy for autoimmune diseases: an update. BMC Med 11: 88.
73. Rutgeerts P. Geboes K. Vantrappen G. Beyls J. Kerremans R. Hiele M. (1990) Predictability of the postoperative course of Crohn's disease. Gastroenterology 99: 956–963.
74. Rutgeerts P. Sandborn W. Fedorak R. Rachmilewitz D. Tarabar D. Gibson P. et al. (2006) Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 888–893.
75. Rutgeerts P. van Assche G. Sandborn W. Wolf D. Geboes K. Colombel J. et al. (2012) Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 142: 1102–1111.
76. Sakuraba A. Keyashian K. Correia C. Melek J. Cohen R. Hanauer S. et al. (2013 a) Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 19: 621–626.
77. Sakuraba A. Annunziata M. Cohen R. Hanauer S. Rubin D. (2013 b) Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis 19: 2577–2583.
78. Salim S. Soderholm J. (2011) Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 17: 362–381.
79. Sandborn W. Abreu M. D'Haens G. Colombel J. Vermeire S. Mitchev K. et al. (2010 a) Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 8: 688–695.
80. Sandborn W. Colombel J. Enns R. Feagan B. Hanauer S. Lawrance I. et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Eng J Med 353: 1912–1925.
81. Sandborn W. Feagan B. (2003) Review article: mild to moderate Crohn's disease – defining the basics for new treatment algorithm. Alim Pharm Ther 18: 263–277.
82. Sandborn W. Feagan B. Fedorak R. Scherl E. Fleisher M. Katz S. et al. (2008) A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 1130–1141.
83. Sandborn W. Feagan B. Rutgeerts P. Hanauer S. Colombel J. Sands B. et al. (2013) Vedolizumab as induction and maintenance therapy for Crohn's disease. N Eng J Med 369: 711–721.
84. Sandborn W. Feagan B. Stoinov S. Honiball P. Rutgeerts P. Mason D. et al. (2007 a) Certolizumab pegol for the treatment of Crohn's disease. N Eng J Med 357: 228–238.
85. Sandborn W. Gasink C. Gao L. Blank M. Johanns J. Guzzo C. et al. (2012) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Eng J Med 367: 1519–1528.
86. Sandborn W. Hanauer S. Katz S. Safdi M. Wolf D. Baerg R. et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088–1094.
87. Sandborn W. Hanauer S. Rutgeerts P. Fedorak R. Lukas M. MacIntosh D. et al. (2007 b) Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 56: 1232–1239.
88. Sandborn W. Lee S. Randall C. Gutierrez A. Schwartz D. Ambarkhane S. et al. (2014) Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Alim Pharm Ther 40: 903–916.
89. Sandborn W. Rutgeerts P. Enns R. Hanauer S. Colombel J. Panaccione R. et al. (2007 c) Adalimumab induction therapy for crohn's disease previously treated with infliximab: A randomized trial. Ann Int Med 146: 829–838.
90. Sandborn W. Schreiber S. Hanauer S. Colombel J. Bloomfield R. Lichtenstein G. et al. (2010 b) Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 8: 696–702
91. Sands B. Anderson F. Bernstein C. Chey W. Feagan B. Fedorak R. et al. (2004 a) Infliximab maintenance therapy for fistulizing Crohn's disease. N Eng J Med 350: 876–885.
92. Sands B. Blank M. Patel K. van Deventer S. (2004 b) Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2: 912–920.
93. Sands B. Kozarek R. Spainhour J. Barish C. Becker S. Goldberg L. et al. (2007) Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 13: 2–11.
94. Sartor R. (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390–407.
95. Schreiber S. Khaliq-Kareemi M. Lawrance I. Thomsen O. Hanauer S. McColm J. et al. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Eng J Med 357: 239–250.
96. Schreiber S. Rutgeerts P. Fedorak R. Khaliq–Kareemi M. Kamm M. Boivin M. et al. (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807–818.
97. Shivananda S. Lennard-Jones J. Logan R. Fear N. Price A. Carpenter L. et al. (1996) Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39: 690–697.
98. Singh J. Wells G. Christensen R. Tanjong Ghogomu E. Maxwell L. MacDonald J. et al. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 16 February 2011. DOI: 10.1002/14651858.CD008794.pub2.
99. Sokol H. Seksik P. Furet J. Firmesse O. Nion-Larmurier I. Beaugerie L. et al. (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15: 1183–1189.
100. Targan S. Feagan B. Fedorak R. Lashner B. Panaccione R. Present D. et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132: 1672–1683.
101. Targan S. Hanauer S. van Deventer S. Mayer L. Present D. Braakman T. et al. (1997) A short-term study of chimeric monoclonal antibody cA 2 to tumor necrosis factor α for Crohn's disease. N Eng J Med 337: 1029–1036.
102. van Assche G. Dignass A. Reinisch W. van der Woude C. Sturm A. de Vos M. et al. (2010) The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 4: 63–101.
103. van Assche G. van Ranst M. Sciot R. Dubois B. Vermeire S. Noman M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Eng J Med 353: 362–368.
104. van Assche G. Vermeire S. Ballet V. Gabriels F. Noman M. D'Haens G. et al. (2012) Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 61: 229–234.
105. van Deventer S. (1999) Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis 58: I114–I120.
106. van Dullemen H. van Deventer S. Hommes D. Bijl H. Jansen J. Tytgat G. et al. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129–135.
107. Verbeeck J. van Assche G. Ryding J. Wollants E. Rans K. Vermeire S. et al. (2008) JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?. Gut 57: 1393–1397.
108. Villablanca E. Cassani B. von Andrian U. Mora J. (2011) Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 140: 1776–1784.
109. Vultaggio A. Matucci A. Nencini F. Pratesi S. Parronchi P. Rossi O. et al. (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65: 657–661.
110. Waugh A. Garg S. Matic K. Gramlich L. Wong C. Sadowski D. et al. (2010) Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Alim Pharm Ther 32: 1129–1134.
111. Xavier R. Podolsky D. (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427–434.
112. Zelinkova Z. van der Ent C. Bruin K. van Baalen O. Vermeulen H. Smalbraak H. et al. (2013) Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 11: 318–321.
113. Zhang Y. Li Y. (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20: 91.